Vaccinex Sees Mixed Signals In Huntington’s Study

Pepinemab Missed Key Endpoints In Phase II Trial

Sep 22 2020

However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.

Hand flip wooden cube with the word PLAN A to PLAN B on white background. Business concept — With mixed data in Huntington's, Vaccinex turns attention to Alzheimer's

Vaccinex, Inc.’s potentially disease-modifying therapy for Huntington’s disease missed its key endpoints in top-line data unveiled 22 September from the Phase II SIGNAL study, but the biotech thinks the novel drug offers potential in both Alzheimer’s disease and also later-stage Huntington’s patients than those included in the trial.

The company noted that in cohort B1 of SIGNAL – testing the semaphorin 4D (SEMA4D) inhibitor pepinemab in 179 early...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

Oct 08 2025

• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

Oct 08 2025

• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

Oct 08 2025

• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.